
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc demonstrated strong financial performance, achieving a 21% increase in top-line revenue in Q3, bolstered by 13% growth in volume and a 5% rise in average selling prices. The company also reported its highest cash collections in history during October and delivered a positive GAAP net income, raising both its revenue and earnings guidance. Furthermore, the significant expansion of its sales force by approximately 50% is expected to drive future volume growth, reflecting the company's positive business fundamentals and optimistic outlook.
Bears say
CareDx Inc. reported Q3'25 testing volumes of 50,000, reflecting a modest year-over-year growth of 13% but falling short of expectations, which raises concerns about future growth potential. The company faces challenges with a significant reliance on its testing services and may struggle to commercialize new diagnostic solutions crucial for its expansion strategy, compounded by inconsistencies in management over the past three years. Additionally, with shares trading at 1.4 times the estimated 2026 revenue of $415 million, well below historical averages and relative to peers in the diagnostics sector, there are apprehensions regarding the company’s long-term valuation and growth trajectory.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares